Lexicon Pharmaceuticals, Inc. (LXRX) Announces Management Change

THE WOODLANDS, Texas, Feb. 23, 2015 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the resignation of Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer, to pursue another opportunity.  Dr. Zambrowicz will be assisting in shifting his responsibilities to other members of the company in order to ensure a seamless transition.  In connection with the change, Lexicon will merge its discovery and clinical functions and conduct an immediate search for a head of research and development.  Dr. Zambrowicz has agreed to be available to provide consulting services as the company completes this transition.

"On behalf of everyone at Lexicon, I would like to thank Brian for his years of dedication, service and commitment in leading Lexicon's discovery efforts from its infancy to a company with two lead drug programs for diabetes and carcinoid syndrome in Phase 3 development," said Lonnel Coats, Lexicon's president and chief executive officer.  "I wish him all the best in his future endeavors."

About Lexicon
Lexicon is a biopharmaceutical company focused on developing breakthrough treatments for human disease.  Lexicon has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to meet its capital requirements, successfully conduct preclinical and clinical development of its drug candidates, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lexicon-announces-management-change-300039893.html

SOURCE Lexicon Pharmaceuticals, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.